Mass spectrometry based proteomics in the diagnosis of kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 3, 2013, Pages 273-280

  Sethi, Sanjeev ^a   Vrana, Julie A ^a   Theis, Jason D ^a   Dogan, Ahmet ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloid; Fibrillary glomerulonephritis; Immunotactoid glomerulopathy; Laser microdissection; Mass spectrometry; Proteomics

Indexed keywords

AMYLOID PROTEIN; COMPLEMENT FACTOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

AMYLOIDOSIS; ANTIGEN ANTIBODY COMPLEX; C3 GLOMERULONEPHRITIS; CLINICAL LABORATORY; COMPLEMENT ALTERNATIVE PATHWAY; CRESCENTIC GLOMERULONEPHRITIS; DENSE DEPOSIT DISEASE; FIBRILLARY GLOMERULONEPHRITIS; GLOMERULONEPHRITIS; GLOMERULOPATHY; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOTACTOID GLOMERULOPATHY; KIDNEY AMYLOIDOSIS; KIDNEY DISEASE; LASER MICRODISSECTION; MASS SPECTROMETRY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NECROTIC GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEOMICS; REVIEW;

AMYLOIDOSIS; BIOLOGICAL MARKERS; COMPLEMENT SYSTEM PROTEINS; GLOMERULONEPHRITIS; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOGLOBULINS; KIDNEY; KIDNEY DISEASES; LASER CAPTURE MICRODISSECTION; MASS SPECTROMETRY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOMICS;

EID: 84878872967     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835fe37c     Document Type: Review

References (28)

1. Weening J, Jennette JC. Historical milestones in renal pathology. Virchows Archiv 2012; 461:3-11.
2. Sethi S, Gamez JD, Vrana JA, et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 2009; 75:952-960.
3. Sethi S, Theis JD, Leung N, et al. Mass spectrometry based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Neph 2010; 5:2180-2187.
4. Sethi S, Vrana JA, Theis JD, et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82:226-234.
5. Murphy CL, Wang S, Williams T, et al. Characterization of systemic amyloid deposits by mass spectrometry. Meth Enzymol 2006; 412:48-62.
6. Choi N, Nakano Y, Tobe T, et al. Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement. Int Immunol 1990; 2:413-417.
7. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75:4646-4658.
8. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74:5383-5392.
9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-596.
10. Sethi S, Theis JD, Shiller SM, et al. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 2012; 81:201-206.
11. Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012; 120:3206-3213.
12. Vrana JA, Gamez JD, Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 2009; 114:4957-4959.
13. Saha A, Theis JD, Vrana JA, et al. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant 2011; 26:2407-2412.
14. Nasr SH, Valeri AM, Cornell LD, et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6:775-784.
15. Sethi S, Theis J, Vrana J, et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic glomerulonephritis, fibrillary glomerulonephritis and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013. [Epub ahead of print]
16. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: a new look at an old entity. N Engl J Med 2012; 366:1119-1131.
17. Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Neph 2010; 5:770-782.
18. Jain D, Abdel-Kader K, Yenchek R, et al. Clinical utility of mass spectrometrybased proteomics in the diagnosis of monoclonal gammopathy- associated membranoproliferative glomerulonephritis [abstract]. In: Kidney Week 2012; 30 October - 4 November 2012; San Diego, CA. American Society of Nephrology. 2012; TH-PO1100.
19. Fakhouri F, Fremeaux-Bacchi V, Noel L-H, et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6:494-499.
20. Sethi S, Nester CM, Smith RJH. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int 2012; 81:434-441.
21. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 2005; 16:1392-1403.
22. Sethi S, Fervenza FC, Zhang Y, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82:465-473.
23. Radhakrishnan S, Lunn A, Kirschfink M, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 2012; 366:1165-1166.
24. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med 2012; 366:1161-1163.
25. Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 2012; 23:1229-1237.
26. Zhou XJ, Silva FG. Membranoproliferative glomerulonephritis. In: Jennette JC, Olson LJ, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007 . pp. 253-319.
27. Falk RJ, Jennette JC. ANCA disease: where is this field heading? J Am Soc Nephrol 2010; 21:745-752.
28. Fervenza FC, Smith RJH, Sethi S. Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis 2012; 60:126-132.